Fennec Net Income Applicable To Common Shares from 2010 to 2026
| FENC Stock | USD 7.56 0.29 3.69% |
Net Loss | First Reported 2000-06-30 | Previous Quarter -6.1 M | Current Value -5.4 M | Quarterly Volatility 2.5 M |
Check Fennec Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fennec Pharmaceuticals' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 874 K or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 3.96, Dividend Yield of 0.0 or Days Sales Outstanding of 108. Fennec financial statements analysis is a perfect complement when working with Fennec Pharmaceuticals Valuation or Volatility modules.
Fennec | Net Income Applicable To Common Shares | Build AI portfolio with Fennec Stock |
Latest Fennec Pharmaceuticals' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Fennec Pharmaceuticals over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Fennec Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fennec Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Fennec Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (10,304,298) | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | (100.91) | |
| Mean Deviation | 9,241,845 | |
| Median | (9,888,000) | |
| Standard Deviation | 10,397,629 | |
| Sample Variance | 108.1T | |
| Range | 28.4M | |
| R-Value | (0.95) | |
| Mean Square Error | 11.2T | |
| R-Squared | 0.90 | |
| Slope | (1,956,196) | |
| Total Sum of Squares | 1729.8T |
Fennec Net Income Applicable To Common Shares History
About Fennec Pharmaceuticals Financial Statements
Fennec Pharmaceuticals stakeholders use historical fundamental indicators, such as Fennec Pharmaceuticals' Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Fennec Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fennec Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Fennec Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fennec Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -21.3 M | -20.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:Check out the analysis of Fennec Pharmaceuticals Correlation against competitors. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Will Biotechnology sector continue expanding? Could Fennec diversify its offerings? Factors like these will boost the valuation of Fennec Pharmaceuticals. Market participants price Fennec higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fennec Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth 0.787 | Return On Assets | Return On Equity |
Understanding Fennec Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Fennec's accounting equity. The concept of intrinsic value—what Fennec Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Fennec Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Fennec Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.